Full Breakdown
Trump Administration’s De Minimis Rule Threatens Access to Affordable Prescription Drugs
By Drooid · · How we work
Core Change and Immediate Impact
U.S. Customs and Border Protection will suspend the “de minimis” exemption that allowed shipments under $800 to enter duty-free. Effective October 22, any prescription drug mailed from abroad will require detailed documentation, a customs bond, and FDA product classifications. The change could delay or increase the cost of low-price medicines imported from Canada, Australia, New Zealand or the United Kingdom.
Background & Context
President Donald Trump has promoted drug-price reductions, citing “most-favoured-nation” agreements that the administration says will save $600 billion over ten years. An executive order in 2020 permitted states, wholesalers and pharmacies to import Canadian medicines, later highlighted by the government-run website TrumpRx. The de minimis rule, originally aimed at curbing illicit synthetic opioids from China, was expanded in 2025 to cover all low-value shipments, raising concerns it will unintentionally restrict legitimate personal-use imports.
Data & Statistics
- A 2020 JAMA Network study found 2.3 million Americans purchased drugs abroad.
- CPPI estimates over 4 million U.S. consumers buy cheaper prescriptions from foreign pharmacies, saving 52 %–89 % on 90-day supplies.
- A three-month supply of Eliquis costs $565 from a Canadian mail-order pharmacy versus $1,017 on Amazon Pharmacy.
- Wellbutrin XL 300 mg: U.S. retail price exceeds $2,500 per month, while a three-month Canadian supply is under $200.
Official Statements & Responses
CBP and the FDA have not responded to requests for comment on the rule’s implementation.
Criticism & Opposition
Ken Hunter, executive director of CPPI, warned that the rule will cause “costs to explode” for many medications. Florida Representatives Aaron Bean, Gus M. Bilirakis and C. Scott Franklin signed a letter demanding protection for Floridians seeking relief from high drug prices. More than 70 Democrats also requested a pause until assurances are provided that personal-use prescriptions can still enter the United States.
Conflicting Reports & Gaps
Sources differ on how many Americans rely on foreign pharmacies: the JAMA study cites 2.3 million, while CPPI estimates over 4 million. Neither CBP nor the FDA has issued detailed guidance on how the new documentation and bond requirements will be applied to personal-use prescriptions, leaving a gap in clarity for consumers and importers.
Verbatim Quotes
- “The issue is a matter of life and death for me,” — Susan Hooper, 75, Toledo, Ohio
- “I’ve had so many of our members calling me and telling me, ‘I don’t know what I’m going to do,’” — Ken Hunter, CPPI
- “Give that price differential more than a 5-second consideration,” — Joe Graedon, pharmacologist, The People’s Pharmacy
What’s Next
The October 22 deadline marks the first day the new requirements will be enforced; shipments must be in recipients’ mailboxes by that date. CPPI is urging Americans to contact congressional offices, hoping the White House will intervene before the rule takes full effect. Lawmakers and consumer-advocacy groups are expected to intensify lobbying as the deadline approaches.